Funding
Funding not disclosed
Founders
Product
Problem
Traditional cancer treatments like chemotherapy and radiation can be highly toxic and lack specificity, damaging healthy cells alongside cancerous ones. This can lead to severe side effects and reduced quality of life for patients. Existing CAR T-cell therapies, while promising, can be limited by manufacturing complexities and accessibility.
Solution
Living Pharma is developing personalized CAR T-cell therapies that leverage a patient's own immune cells to precisely target and eliminate cancer cells. This approach aims to minimize off-target effects and improve treatment efficacy compared to conventional methods. By genetically modifying a patient's T cells to express a chimeric antigen receptor (CAR) that recognizes specific cancer antigens, Living Pharma's therapies direct the immune system to selectively attack tumor cells while sparing healthy tissue. The company is focused on streamlining the manufacturing process to enhance accessibility and reduce the time required to deliver personalized treatments to patients.
Target Audience
The primary target audience includes patients with cancers that have not responded to standard treatments, as well as oncologists and hematologists seeking more targeted and effective therapies.
Features
- Personalized CAR T-cell therapy using a patient's own T cells
- CAR design targeting specific cancer antigens for selective tumor cell destruction
- Streamlined manufacturing process for faster treatment delivery